First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

“Due to the progressive nature of polyneuropathy of hereditary transthyretin-mediated amyloidosis, it is critical to have timely diagnosis and new therapies to help people have greater control over ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Hereditary transthyretin amyloidosis with polyneuropathy (damage to your peripheral nerves), (hATTR-PN), is a rare disease ...

A rabbit sensitized with myelin lipid galactocerebroside develops autoimmune demyelinating polyneuropathy. The nerve conduction study was performed prior to sensitization (a) and at the peak of ...

Moreover, Immunovant’s ongoing and upcoming clinical trials for batoclimab in myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease provide additional potential ...

Intellia Therapeutics Inc (NTLA) showcases strong financials and significant progress in its CRISPR-based pipeline, despite ...

In addition, we're making excellent progress across our other late-stage trials. As announced this morning, the FDA cleared ...

According to analysts' consensus estimate, Intellia Therapeutics (NASDAQ: NTLA), a clinical-stage biotech, boasts a ...